Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 33.24
SRPT's Cash to Debt is ranked higher than
70% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. SRPT: 33.24 )
SRPT' s 10-Year Cash to Debt Range
Min: 4.43   Max: No Debt
Current: 33.24

Equity to Asset 0.84
SRPT's Equity to Asset is ranked higher than
86% of the 1086 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SRPT: 0.84 )
SRPT' s 10-Year Equity to Asset Range
Min: -0.06   Max: 0.97
Current: 0.84

-0.06
0.97
F-Score: 2
Z-Score: 3.08
M-Score: -2.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1371.21
SRPT's Operating margin (%) is ranked higher than
55% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. SRPT: -1371.21 )
SRPT' s 10-Year Operating margin (%) Range
Min: -28680.87   Max: -71.16
Current: -1371.21

-28680.87
-71.16
Net-margin (%) -1391.71
SRPT's Net-margin (%) is ranked higher than
55% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -76.91 vs. SRPT: -1391.71 )
SRPT' s 10-Year Net-margin (%) Range
Min: -27020   Max: -4.93
Current: -1391.71

-27020
-4.93
ROE (%) -51.83
SRPT's ROE (%) is ranked higher than
65% of the 1318 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. SRPT: -51.83 )
SRPT' s 10-Year ROE (%) Range
Min: -309.2   Max: -16.44
Current: -51.83

-309.2
-16.44
ROA (%) -44.72
SRPT's ROA (%) is ranked higher than
63% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. SRPT: -44.72 )
SRPT' s 10-Year ROA (%) Range
Min: -184.14   Max: -4.62
Current: -44.72

-184.14
-4.62
ROC (Joel Greenblatt) (%) -452.66
SRPT's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 1405 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. SRPT: -452.66 )
SRPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2075   Max: -277.71
Current: -452.66

-2075
-277.71
Revenue Growth (3Y)(%) -52.10
SRPT's Revenue Growth (3Y)(%) is ranked higher than
58% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. SRPT: -52.10 )
SRPT' s 10-Year Revenue Growth (3Y)(%) Range
Min: -63.2   Max: 383.5
Current: -52.1

-63.2
383.5
EBITDA Growth (3Y)(%) 26.60
SRPT's EBITDA Growth (3Y)(%) is ranked higher than
90% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. SRPT: 26.60 )
SRPT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -36.3   Max: 43.4
Current: 26.6

-36.3
43.4
EPS Growth (3Y)(%) 213.50
SRPT's EPS Growth (3Y)(%) is ranked higher than
100% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. SRPT: 213.50 )
SRPT' s 10-Year EPS Growth (3Y)(%) Range
Min: -62.4   Max: 213.5
Current: 213.5

-62.4
213.5
» SRPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SRPT Guru Trades in Q1 2014

Columbia Wanger 2,635,000 sh (unchged)
Columbia Wanger 2,633,000 sh (-0.08%)
Steven Cohen 641,600 sh (-9.86%)
George Soros 25,000 sh (-89.27%)
» More
Q2 2014

SRPT Guru Trades in Q2 2014

George Soros 680,000 sh (+2620.00%)
Steven Cohen 272,100 sh (unchged)
Columbia Wanger 2,633,000 sh (unchged)
» More
Q3 2014

SRPT Guru Trades in Q3 2014

Columbia Wanger 3,237,000 sh (+22.94%)
Steven Cohen 691,200 sh (unchged)
Steven Cohen 227,300 sh (-16.46%)
George Soros 325,000 sh (-52.21%)
» More
Q4 2014

SRPT Guru Trades in Q4 2014

Jim Simons 164,278 sh (New)
Steven Cohen 1,551,300 sh (+582.49%)
Steven Cohen 1,826,500 sh (+17.74%)
Columbia Wanger 3,272,400 sh (+1.09%)
Columbia Wanger 3,272,400 sh (unchged)
Steven Cohen 275,200 sh (unchged)
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SRPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.20
SRPT's P/B is ranked higher than
87% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. SRPT: 2.20 )
SRPT' s 10-Year P/B Range
Min: 1.61   Max: 234
Current: 2.2

1.61
234
P/S 54.00
SRPT's P/S is ranked higher than
50% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 37.00 vs. SRPT: 54.00 )
SRPT' s 10-Year P/S Range
Min: 1.56   Max: 2244
Current: 54

1.56
2244
EV-to-EBIT -2.62
SRPT's EV-to-EBIT is ranked higher than
55% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. SRPT: -2.62 )
SRPT' s 10-Year EV-to-EBIT Range
Min: -29.1   Max: -0.8
Current: -2.62

-29.1
-0.8
Current Ratio 6.72
SRPT's Current Ratio is ranked higher than
81% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. SRPT: 6.72 )
SRPT' s 10-Year Current Ratio Range
Min: 0.83   Max: 35.4
Current: 6.72

0.83
35.4
Quick Ratio 6.72
SRPT's Quick Ratio is ranked higher than
82% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. SRPT: 6.72 )
SRPT' s 10-Year Quick Ratio Range
Min: 0.83   Max: 35.4
Current: 6.72

0.83
35.4
Days Sales Outstanding 90.38
SRPT's Days Sales Outstanding is ranked higher than
77% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. SRPT: 90.38 )
SRPT' s 10-Year Days Sales Outstanding Range
Min: 28.22   Max: 886.65
Current: 90.38

28.22
886.65

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.40
SRPT's Price/Net Cash is ranked higher than
93% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 109.90 vs. SRPT: 3.40 )
SRPT' s 10-Year Price/Net Cash Range
Min: 3.35   Max: 28.2
Current: 3.4

3.35
28.2
Price/Net Current Asset Value 3.40
SRPT's Price/Net Current Asset Value is ranked higher than
93% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 45.70 vs. SRPT: 3.40 )
SRPT' s 10-Year Price/Net Current Asset Value Range
Min: 2.98   Max: 10.81
Current: 3.4

2.98
10.81
Price/Tangible Book 2.30
SRPT's Price/Tangible Book is ranked higher than
91% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. SRPT: 2.30 )
SRPT' s 10-Year Price/Tangible Book Range
Min: 2.41   Max: 474
Current: 2.3

2.41
474
Price/Median PS Value 2.20
SRPT's Price/Median PS Value is ranked higher than
71% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. SRPT: 2.20 )
SRPT' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 76.32
Current: 2.2

0.08
76.32
Earnings Yield (Greenblatt) -37.40
SRPT's Earnings Yield (Greenblatt) is ranked lower than
65% of the 1393 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. SRPT: -37.40 )
SRPT' s 10-Year Earnings Yield (Greenblatt) Range
Min: -53.7   Max: 0
Current: -37.4

-53.7
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:AB3A.Germany,
Sarepta Therapeutics Inc was incorporated in the State of Oregon on July 22, 1980. The Company discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The Company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases.
» More Articles for SRPT

Headlines

Articles On GuruFocus.com
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Mar 16 2013 
comment on SRPT Feb 16 2013 

More From Our Partners
Tekmira Up on Ebola Candidate Update from the FDA - Analyst Blog Apr 13 2015 - ZACKS

More From Other Websites
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other... Apr 20 2015
Tekmira Up on Ebola Candidate Update from the FDA - Analyst Blog Apr 13 2015
4 Stocks Rising on Unusual Volume to Trade for Breakouts Apr 06 2015
SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Apr 02 2015
Sarepta CEO Exits, Eteplirsen Regulatory Filing on Track - Analyst Blog Apr 01 2015
Stock Pops & Drops: SRPT, KORS, DAL & GPRO Apr 01 2015
Sarepta Therapeutics CEO Resigns Amid Tumult With the FDA Apr 01 2015
Sarepta Therapeutics: Why CEO Resignation is Good News Apr 01 2015
Sarepta CEO Quits; Successor Pledges to Work Better With FDA Apr 01 2015
Stock Futures Down, Not Diving; Jobs Data Slip To 11-Month Low Apr 01 2015
Sarepta Therapeutics CEO Chris Garabedian resigns Apr 01 2015
Sarepta shares rally 10% as company names interim CEO Apr 01 2015
Sarepta Therapeutics Inc. Appoints Edward Kaye, M.D., as Interim CEO and Management Update Call... Apr 01 2015
Early movers: SHLD, WMT, GDDY, AAPL & more Apr 01 2015
An Interview With Sarepta's New CEO Mar 31 2015
Sudden Exit of Sarepta CEO Fuels Speculation That Soured FDA Relationship Is to Blame Mar 31 2015
Sarepta Therapeutics Appoints Edward Kaye, M.D., as Interim CEO; Company on Track with Clinical and... Mar 31 2015
Sarepta Therapeutics Appoints Edward Kaye, M.D., as Interim CEO; Company on Track with Clinical and... Mar 31 2015
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2014 Financial Results and Recent... Mar 24 2015
Sarepta Therapeutics' 3 Biggest Risks Mar 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK